Cargando…

Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis

BACKGROUND: A significant percentage of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) achieve clinically meaningful improvement when receiving placebo or tadalafil 5mg once daily. However, individual patient characteristics associated with treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fusco, Ferdinando, D’Anzeo, Gianluca, Henneges, Carsten, Rossi, Andrea, Büttner, Hartwig, Nickel, J. Curtis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540425/ https://www.ncbi.nlm.nih.gov/pubmed/26284523 http://dx.doi.org/10.1371/journal.pone.0135484

Ejemplares similares

Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities
por: Hatzichristou, Dimitrios, et al.
Publicado: (2015)

Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy
por: Moncada, Ignacio, et al.
Publicado: (2014)

Urinary tract infections in women: etiology and treatment options
por: Minardi, Daniele, et al.
Publicado: (2011)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
por: Lee, Sung Won, et al.
Publicado: (2014)

Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV study
por: Patel, Hitendra R, et al.
Publicado: (2015)

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
por: Angalakuditi, Mallik, et al.
Publicado: (2010)

Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis
por: Cui, Jianwei, et al.
Publicado: (2021)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
por: Pogula, Vedamurthy Reddy, et al.
Publicado: (2019)

Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction
por: Ahn, Sun Tae, et al.
Publicado: (2020)

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
por: Ahmad, Malik Suhail, et al.
Publicado: (2022)

Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
por: Pattanaik, Smita, et al.
Publicado: (2019)

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus
por: Elkelany, Osama O, et al.
Publicado: (2015)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Publicado: (2019)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
por: Alsaikhan, Bader, et al.
Publicado: (2014)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials
por: Guo, Boda, et al.
Publicado: (2020)

Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study
por: Yamazaki, Hiroyoshi, et al.
Publicado: (2020)

Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: a systematic review of the literature and narrative synthesis
por: Mari, Andrea, et al.
Publicado: (2021)

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia
por: Tanaka, Tomoaki, et al.
Publicado: (2018)

Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study
por: Won, Ji Eon, et al.
Publicado: (2018)

Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study
por: Fusco, Ferdinando, et al.
Publicado: (2018)

Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Creta, Massimiliano, et al.
Publicado: (2023)

Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation
por: Alhakamy, Nabil A., et al.
Publicado: (2019)

Sexual asthenia: Tradamixina versus Tadalafil 5 mg daily
por: Iacono, Fabrizio, et al.
Publicado: (2012)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
por: Zhou, Rui, et al.
Publicado: (2023)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Effect of a tadalafil 5-mg single daily dose on lifelong premature ejaculation: A single-blinded placebo-controlled study
por: Abou Faddan, Amr Hassan, et al.
Publicado: (2022)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Effect of tadalafil 5mg daily treatment on the ejaculatory times, lower urinary tract symptoms and erectile function in patients with erectile dysfunction
por: Karabakan, Mehmet, et al.
Publicado: (2017)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma
por: Abdel Moneim, Mona M.
Publicado: (2022)

Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial
por: Sebastianelli, Arcangelo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ig093ik07dvcgu9oquqt8p0vao